TG Therapeutics announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis, RMS, at the American Academy of Neurology, AAN, annual meeting. Michael Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, "We are pleased to present additional analyses from the ULTIMATE I & II Phase 3 trials and further in-vitro characterization of BRIUMVI at the AAN conference this week. We look forward to continuing to share additional exploratory analyses throughout the year."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics price target raised to $28 from $24 at H.C. Wainwright
- TG Therapeutics Blasts Up on Analyst Praise
- BofA questions relevance of Briumvi tracking to Q1 beat, says TG move ‘overdone’
- TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
- TG Therapeutics announces positive CHMP opinion for BRIUMVI